Effect of peptichemio in nonlocalized neuroblastoma

PTC, a mixture of oligopeptides of m‐L‐sarcholysin, acting primarily as an alkylating agent, was utilized as initial therapy following diagnosis in 80 children with nonlocalized neuroblastoma. Of the 67 evaluable patients (21 Stage III, 41 Stage IV and five Stage IV‐S), 51 had measurable lesions all...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 1982-07, Vol.50 (1), p.10-17
Main Authors: De Bernardi, Bruno, Pastore, Guido, Carli, Modesto, Ceci, Adriana, Paolucci, Guido, Madon, Enrico, Mancini, Antonia, Tamaro, Paolo, Rebuffi, Luisa, Colella, Roberto, Cozzutto, Cleto
Format: Article
Language:English
Subjects:
Adolescent
Child
Child, Preschool
Female
Humans
Infant
Male
Melphalan - analogs & derivatives
Neuroblastoma - drug therapy
Neuroblastoma - mortality
Neuroblastoma - radiotherapy
Peptichemio - therapeutic use
Vincristine - therapeutic use
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:PTC, a mixture of oligopeptides of m‐L‐sarcholysin, acting primarily as an alkylating agent, was utilized as initial therapy following diagnosis in 80 children with nonlocalized neuroblastoma. Of the 67 evaluable patients (21 Stage III, 41 Stage IV and five Stage IV‐S), 51 had measurable lesions allowing to evaluate PTC activity; objective tumor responses to the drug were recorded in 45 of these 51 cases (88.2%): 5/5 Stage III, 37/41 Stage IV, 3/5 Stage IV‐S. Complete responses were obtained in seven patients (13.7%), partial responses in 32 (62.7%), objective improvement in six (11.8%). Four patients (7.8%) had either no tumor change, or tumor progression. There have been two early drug‐related deaths (3.9%). Stage III and IV patients responding to PTC were then treated by irradiation + VCR, followed by cycle of a combination of Adriamycin, vincristine, and cyclophosphamide. Stage IV‐S patients received no further therapy. Thirteen of 21 Stage III (61.9%), five of 41 Stage IV (12.2%) and four of five Stage IV‐S (80%) are presently alive from 19–48 months (median, 27 months). PTC is an effective agent in advanced neuroblastoma. However, the results of this report do not indicate that its addition to a “standard” treatment, at least in the schedule adopted in this protocol, has improved the final outcome of children with nonlocalized disease.
ISSN:0008-543X
1097-0142
DOI:10.1002/1097-0142(19820701)50:1<10::AID-CNCR2820500104>3.0.CO;2-9